CoChat

Modeling Breast Cancer–Associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior

Dimri, Manjari, Naramura, Mayumi, Duan, Lei, Chen, Jing, Ortega-Cava, Cesar, Chen, Gengsheng, Goswami, Rasna, Fernandes, Norvin, Gao, Qingshen, Dimri, Goberdhan P., Band, Vimla, Band, Hamid · 2007 · Cancer Research

Published version of a preprint

Cited by 65

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, is overexpressed in as many as 60% cases of breast and other cancers. EGFR overexpression is a characteristic of highly aggressive molecular subtypes of breast cancer with basal-like and BRCA1 mutant phenotypes distinct from ErbB2-overexpressing breast cancers. Yet, EGFR is substantially weaker compared with ErbB2 in promoting the oncogenic transformation of nontumorigenic human mammary epithelial cells (human MEC), suggesting a role for cooperating oncogenes. Here, we have modeled the co-overexpression of EGFR and a biologically and clinically relevant potential modifier c-Src in two distinct immortal but nontumorigenic human MECs. Using a combination of morphologic analysis and confocal imaging of polarity markers in three-dimensional Matrigel culture together with functional analyses of early oncogenic traits, we show for the first time that EGFR and c-Src co-overexpression but not EGFR or c-Src overexpression alone unleashes an oncogenic signaling program that leads to hyperproliferation and loss of polarity in three-dimensional acinar cultures, marked enhancement of migratory and invasive behavior, and anchorage-independent growth. Our results establish that EGFR overexpression in an appropriate context (modeled here using c-Src overexpression) can initiate oncogenic transformation of nontumorigenic human MECs and provide a suitable in vitro model to interrogate human breast cancer–relevant oncogenic signaling pathways initiated by overexpressed EGFR and to identify modifiers of EGFR-mediated breast oncogenesis. [Cancer Res 2007;67(9):4164–72]

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-06-2580

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 43

  1. Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433–57. · DOI · Paper page
  2. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001; 374: 9–15. · DOI · Paper page
  3. Biscardi JS, Ishizawar RC, Silva CM, Parsons SJ. Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2000; 2: 203–10. · DOI · Paper page
  4. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3–11. · DOI · Paper page
  5. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264–71. · DOI · Paper page
  6. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96. · DOI · Paper page
  7. Ansquer Y, Mandelbrot L, Lehy T, et al. Expression of BRCA1, HER-1 (EGFR) and HER-2 in sporadic breast cancer and relationships to other clinicopathological prognostic features. Anticancer Res 2005; 25: 4535–41.
  8. Ji H, Zhao X, Yuza Y, et al. Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A 2006; 103: 7817–22. · DOI · Paper page
  9. Di Fiore PP, Segatto O, Taylor WG, Aaronson SA, Pierce JH. EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science 1990; 248: 79–83. · DOI
  10. Neve RM, Lane HA, Hynes NE. The role of overexpressed HER2 in transformation. Ann Oncol 2001; 12: S9–13. · DOI · Paper page
  11. Yarden Y, Sliwkowski M. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127–37. · DOI · Paper page
  12. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS. ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 2001; 3: 785–92. · DOI · Paper page
  13. Frame MC. Newest findings on the oldest oncogene; how activated src does it. J Cell Sci 2004; 117: 989–98. · DOI · Paper page
  14. Zhou P, Fernandes N, Dodge IL, et al. ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem 2003; 278: 13829–37. · DOI · Paper page
  15. Duan L, Miura Y, Dimri M, et al. Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem 2003; 278: 28950–60. · DOI · Paper page
  16. Band V, Sager R. Distinctive traits of normal and tumor-derived human mammary epithelial cells expressed in a medium that supports long-term growth of both cell types. Proc Natl Acad Sci U S A 1989; 86: 1249–53. · DOI · Paper page
  17. Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990; 50: 6075–86.
  18. Debnath J, Muthuswamy SK, Brugge JS. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 2003; 30: 256–68. · DOI · Paper page
  19. Dimri GP, Itahana K, Acosta M, Campisi J. Regulation of a senescence checkpoint response by the E2F1 transcription factor and p14(ARF) tumor suppressor. Mol Cell Biol 2000; 20: 273–85. · DOI · Paper page
  20. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 1991; 65: 6671–6. · DOI · Paper page
  21. Ghosh AK, Reddi AL, Rao NL, Duan L, Band V, Band H. Biochemical basis for the requirement of kinase activity for Cbl-dependent ubiquitinylation and degradation of a target tyrosine kinase. J Biol Chem 2004; 279: 36132–41. · DOI
  22. Brugge JS, Debnath J. Modeling glandular epithelial cancers in three dimensional cultures. Nat Rev Cancer 2005; 5: 675–88. · DOI · Paper page
  23. Dimri G, Band H, Band V. Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res 2005; 7: 171–9. · DOI · Paper page
  24. Boehm JS, Hahn WC. Understanding transformation: progress and gaps. Curr Opin Genet Dev 2005; 15: 13–7. · DOI
  25. Zhao J, Roberts TM, Hahn WC. Functional genetics and experimental models of human cancer. Trends Biochem Sci 2004; 10: 344–50. · DOI
  26. Shaw KR, Wrobel CN, Brugge JS. Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J Mammary Gland Biol Neoplasia 2004; 9: 297–310. · DOI
  27. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW. The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 2002; 70: 537–46. · DOI · Paper page
  28. Rotin DB, Margolis M. Mohammadi RJ, et al. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase C. EMBO J 1992; 11: 559–67. · DOI · Paper page
  29. Okabayashi Y, Kido Y, Okutani T, Sugimoto Y, Sakaguchi K, Kasuga M. Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells. J Biol Chem 1994; 269: 18674–8. · DOI · Paper page
  30. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. Oncogene 2004; 23: 8017–23. · DOI · Paper page
  31. Clevenger CV. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 2004; 165: 1449–60. · DOI · Paper page
  32. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Aca Sci U S A 1992; 89: 9064–8. · DOI · Paper page
  33. Klinghoffer RA, Sachsemaier C, Cooper JA, Soriano P. Src family kinases are required for integrin but not PDGFR signal transduction. EMBO J 1999; 18: 2459–71. · DOI · Paper page
  34. Maheshwari G, Wiley HS, Lauffenburger DA. Autocrine epidermal growth factor signaling stimulates directionally persistent mammary epithelial cell migration. J Cell Biol 2001; 155: 1123–8. · DOI
  35. Kendall SD, Linardic CM, Adam SJ, Counter CM. A network of genetic events sufficient to convert normal human cells to a tumorigenic state. Cancer Res 2005; 21: 9824–8. · DOI · Paper page
  36. Andrechek ER, Muller WJ. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res 2000; 2: 211–6. · DOI · Paper page
  37. D'Souza-Schorey C. Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol 2005; 15: 19–26. · DOI · Paper page
  38. Foty RA, Steinberg MS. Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 2004; 48: 397–409. · DOI · Paper page
  39. Bryant DM, Stow JL. The ins and outs of E-cadherin trafficking. Trends Cell Biol 2004; 14: 427–34. · DOI · Paper page
  40. Nam JS, Ino Y, Sakamoto M, Hirohashi S. Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 2002; 8: 2430–6.
  41. Genda T, Sakomoto M, Ichida T, Asakura H, Hirohashi S. Loss of cell -cell contact is induced by integrin-mediated cell-substratum adhesion in highly motile and highly metastatic hepatocellular carcinoma cells. Lab Invest 2000; 80: 387–94. · DOI
  42. Boerner JL, Demory ML, Silva C, Parsons SJ. Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004; 24: 7059–71. · DOI · Paper page
  43. Saal LH, Holm K, Maurer M, et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005; 65: 2554–9. · DOI · Paper page

Cited by

See all 65

Metadata

Authors
Dimri, M., Naramura, M., Duan, L., Chen, J., Ortega-Cava, C., Chen, G., Goswami, R., Fernandes, N., Gao, Q., Dimri, G. P., Band, V., & Band, H.
Affiliations
  • 1Molecular Oncology and Divisions of
  • 4Dana-Farber Cancer Institute, Boston, Massachusetts
  • 2Cancer Biology, Evanston Northwestern Healthcare Research Institute, Department of Medicine, Feinberg School of Medicine;
Venue
Cancer Research
Published
2007-05-01
Volume
67
Issue
9
Pages
4164-4172
ISSN
  • 0008-5472
  • 1538-7445
Cited by
65
References
7
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Modeling Breast Cancer–Associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior. https://app.cochat.ai/papers/10.1158/0008-5472.can-06-2580
The paper
Dimri, M., Naramura, M., Duan, L., Chen, J., Ortega-Cava, C., Chen, G., Goswami, R., Fernandes, N., Gao, Q., Dimri, G. P., Band, V., & Band, H. (2007). Modeling Breast Cancer–Associated c-Src and EGFR Overexpression in Human MECs: c-Src and EGFR Cooperatively Promote Aberrant Three-dimensional Acinar Structure and Invasive Behavior. Cancer Research. https://doi.org/10.1158/0008-5472.can-06-2580

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.